Doxil shortage speeds approval of generic version

After expedited review, the FDA okays the first generic version of Doxil (doxorubicin hydrochloride liposome injection), now in short supply.

Novel assay predicts treatment responses in multiple myeloma

A fluorescent assay has been developed that may help predict which patients with multiple myeloma will respond better to certain treatments. The test can detect those cells that survive chemotherapy and are responsible for disease relapse.

New drug improves survival in multiple myeloma relapse

A recent study investigated the safety, efficacy, and maximum tolerated dose of pomalidomide for patients with multiple myeloma whose disease relapsed after treatments with other drugs such as bortezomib and lenalidomide.

New multiple myeloma drug is promising in the treatment of advanced disease

A new oral agent is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a recently reported, multicenter, phase II study.

Pomalidomide extends survival in multiple myeloma

A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.

Vincristine (Oncovin, Vincasar)

Vincristine is a vinca alkaloid indicated for the treatment of certain cancers, and may also be used in some combination therapies.

Persistent headache plagues an immunocompromised patient

Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient's unexplained neurologic symptoms.

Carfilzomib produced significant clinical benefit in multiple myeloma

A study showed durable responses to and acceptable tolerability for carfilzomib (Kyprolis), okayed last month for advanced multiple myeloma.

Clinical Trial: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Clinical Trial: Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Clinical Trial: GDC-0449 in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma Who Received an Autologous Stem Cell Transplant